AlzeCure Pharma AB (publ) (FN STO: ALZCUR), which develops small-molecule drug candidates for CNS diseases with a focus on Alzheimer’s disease and pain, today announced that the company will present at Aktiespararna’s investor evening “Aktiemarknadens nuläge med Oliver Uutisalo samt AlzeCure Pharma” in Stockholm on Wednesday, 14 October.
At the event, AlzeCure’s CEO Martin Jönsson will provide an update on the company and its project portfolio, including following the recently signed collaboration and outlicensing agreements with Eli Lilly and QuantumCell ApS. Aktiespararna’s analyst Oliver Uutisalo will also take part in the evening, sharing his view on the current state of the stock market.
Presentation time: 18:00 CEST
Venue: Aulan, Medborgarskolan, Hagagatan 23 A, Stockholm, Sweden
The presentation will be held in Swedish. More information and registration are available on Aktiespararna’s website: https://www.aktiespararna.se/aktiviteter/aktiemarknadens-nulage-med-oliver-uutisalo-samt-alzecure-pharma-84493
The presentation will also be available afterwards on AlzeCure’s website: https://www.alzecurepharma.se/en/presentations-and-interviews/
